Liver Drug Approval and Pipeline Data Could Be a Game Changer for Gilead Sciences (GILD)
In recent weeks, Gilead Sciences announced Health Canada’s conditional approval of LYVDELZI (seladelpar) for primary biliary cholangitis, and…
Browsing Tag